PHAS

PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS

Overview Fund Activity
Delisted

PHAS was delisted on the 2nd of November, 2022.

Back to rankings

56 hedge funds and large institutions have $38.9M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 17 reducing their positions, and 6 closing their positions.

Holders
56
Holders Change
+5
Holders Change %
+9.8%
% of All Funds
0.89%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
13
Reduced
17
Closed
6
Calls
$118K
Puts
$14K
Net Calls
+$104K
Net Calls Change
-$33K

Top Buyers

1
MCM
1
MAI Capital Management
Ohio
$1.87M
2
TCM
2
Towercrest Capital Management
Pennsylvania
$1.39M
3
VPW
3
Vericrest Private Wealth
Pennsylvania
$1.39M
4
Renaissance Technologies
4
Renaissance Technologies
New York
$118K
5
Geode Capital Management
5
Geode Capital Management
Massachusetts
$423K

Top Sellers

1
Wellington Management Group
1
Wellington Management Group
Massachusetts
$2.21M
2
ECM
2
ExodusPoint Capital Management
New York
$0
3
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$0
4
SWM
4
Spire Wealth Management
Virginia
$11K
5
Marshall Wace
5
Marshall Wace
United Kingdom
$292K
Name Holding Trade Value Shares
Change 		Shares
Change %
Simplex Trading
51
Simplex Trading
Illinois
$1K -$11.6K -10,798 -92%
CG
52
Cutler Group
California
$1K – – –
BNP Paribas Financial Markets
53
BNP Paribas Financial Markets
France
$104 – – –
ECM
54
ExodusPoint Capital Management
New York
– -$1.03M -394,211 Closed
Susquehanna International Group
55
Susquehanna International Group
Pennsylvania
– -$713K -273,100 Closed
Citadel Advisors
56
Citadel Advisors
Florida
– -$98K -37,452 Closed
XT
57
XTX Topco
Cayman Islands
– -$41K -15,574 Closed
D.E. Shaw & Co
58
D.E. Shaw & Co
New York
– -$31K -11,796 Closed
SIG
59
Sargent Investment Group
Maryland
– -$30K -11,675 Closed
1 2
3